No CrossRef data available.
Article contents
Efficacy and Tolerability of Aripiprazole Intramuscular as Maintenance Treatment in Patients with Paranoid Schizophrenia
Published online by Cambridge University Press: 23 March 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Patients suffering from paranoid schizophrenia, require long-term anti-psychotic treatment, which provide, in addition to adequate efficacy both positive and negative symptoms, a good safety and tolerability profile that would ensure adequate adherence to prevent relapse.
Objectives
To analyze the efficacy, tolerability and therapeutic adherence over a year after the introduction of aripiprazole depot in patients diagnosed with paranoid schizophrenia previously treated with other oral or depot anti-psychotics [1,2,3].
Methods
One-year prospective longitudinal study with a sample size of 23 patients diagnosed with schizophrenia in outpatient treatment. Study variables (baseline, 6 and 12 months): Brief Psychiatric Rating Scale (BPRS), clinical global impression (CGI), mean dose of aripiprazole depot, previous treatments, adherence, relapse rate, prolactin levels, sexual dysfunction, BMIs.
Results
Twenty-three patients (71% men, 29% women) diagnosed with paranoid schizophrenia were identified. Improvement was obtained in the different study variables with statistically significant difference (P ≤ 0.05).
Conclusions
Following the introduction of aripiprazole depot in patients diagnosed with schizophrenia previously treated with other oral or depot anti-psychotics in our study, we conclude that maintaining therapeutic efficacy a better tolerability and safety profile, better therapeutic adherence and consequently lower relapse rate were achieved.
Disclosure of interest
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster Walk: Schizophrenia and Other Psychotic Disorders–Part 4
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S280
- Copyright
- Copyright © European Psychiatric Association 2017
References
Kan, J.M.Sanchez, R.Perry, P.P., et al.Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: A 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 7352012 617624.10.4088/JCP.11m07530CrossRefGoogle Scholar
Matt Shirl, Caroline, M.Perry, Aripiprazole:, A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs 2014; 74: 1097–1110.10.1007/s40265-014-0231-7CrossRefGoogle Scholar
Fleischhacker, W.W.Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014; 205 2:135144.10.1192/bjp.bp.113.134213CrossRefGoogle ScholarPubMed
You have
Access
Comments
No Comments have been published for this article.